Lung Cancer
Advertisement
The trial is the first to evaluate the investigational telomere-targeting agent with a PD-(L)1 inhibitior.
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
The novel B7-H3–targeting antibody-drug conjugate has a novel payload.
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
A researcher discusses the implications of identifying potentially pathogenic bacteria in adenocarcinoma tumors.
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
Valsamo Anagnostou, MD, PhD, discusses advances in the field and her lab's research on the topic.
A new study showed surprising results about lung cancer screening during the pandemic.
The drug combination showed "reduced efficacy" in terms of PFS and OS, officials said.
IDE397, a “potential first-in-class” MAT2A inhibitor, is under evaluation in phase 2 clinical trials.
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
The European Commission’s approval is based on results from the phase 3 FLAURA2 trial.
Most patients who received adjuvant osimertinib achieved MRD negativity.
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
Dr. Spigel speaks about how the American Society of Clinical Oncology Annual Meeting inspires collaboration and discovery.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.